Revenue (Quarterly) Chart

Historical Revenue (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
July 31, 2026 20.10M
April 30, 2026 22.46M
January 31, 2026 16.29M
October 31, 2025 17.54M
July 31, 2025 15.09M
April 30, 2025 12.63M
January 31, 2025 11.54M
October 31, 2024 12.21M
July 31, 2024 9.455M
April 30, 2024 10.62M
January 31, 2024 7.823M
October 31, 2023 6.850M
July 31, 2023 5.916M
April 30, 2023 5.663M
January 31, 2023 4.224M
October 31, 2022 3.958M
July 31, 2022 3.182M
April 30, 2022 4.215M
January 31, 2022 3.152M
October 31, 2021 2.697M
July 31, 2021 3.103M
April 30, 2021 2.962M
January 31, 2021 2.234M
October 31, 2020 2.492M
July 31, 2020 1.955M
Date Value
April 30, 2020 1.527M
January 31, 2020 1.749M
October 31, 2019 1.625M
July 31, 2019 1.302M
April 30, 2019 1.214M
January 31, 2019 0.6632M
October 31, 2018 0.6038M
July 31, 2018 0.475M
April 30, 2018 0.5731M
January 31, 2018 0.5527M
October 31, 2017 0.3503M
July 31, 2017 0.5924M
April 30, 2017 4.875M
January 31, 2017 0.3346M
October 31, 2016 0.2299M
July 31, 2016 0.076M
April 30, 2016 0.6143M
January 31, 2016 0.166M
October 31, 2015 0.0494M
July 31, 2015 0.3811M
April 30, 2015 0.8343M
January 31, 2015 0.00
October 31, 2014 0.00
July 31, 2014 0.00
April 30, 2014 0.4955M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
Healios KK 0.0439M
GNI Group Ltd. 40.23M
AnGes, Inc. 1.876M
ACADIA Pharmaceuticals, Inc. 307.96M
Alkermes Plc 496.01M